Adaptive immune checkpoint (IC) inhibitors targeting programmed cell death protein 1 (PD-1) or its ligand programmed death-ligand 1 (PD-L1) have shown efficacy in treating some cancer types by disrupting inhibitory T cell pathways1–3. The gene discussed is PDCD1; the disease is cancer.